Trial Profile
An open-label, non-randomized study to evaluate the efficacy and safety of BAY94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral beta-amyloid when compared to postmortem histopathology
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use; Registrational
- Sponsors Bayer; Bayer HealthCare; Life Molecular Imaging
- 13 Dec 2023 According to Life Molecular Imaging, company announced that the Japanese Ministry of Health has approved the reimbursement by governmental health insurance of the amyloid Positron Emission Tomography (PET) diagnostic Neuraceq.
- 31 Aug 2015 According to a Piramal Imaging media release, data from this study were published in the current issue of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
- 08 Jun 2015 According to Piramal Imaging media release, results were presented at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).